Radium-223 chloride therapy significantly prolongs median OS time for men with castration-resistant prostate cancer (CRPC) bone metastasis.
Adding weekly paclitaxel to adjuvant FAC therapy offers a modest improvement in disease-free survival for patients with high-risk, node-negative breast cancer.
Crizotinib has a strong response rate, progression-free survival (PFS), and is well tolerated in patients with ALK-positive non-small cell lung cancer (NSCLC).
First-line gefitinib for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation offers survival benefit.
Intercalating erlotinib with platinum-based chemotherapy prolongs progression-free survival (PFS) in first-line advanced non-small cell lung cancer (NSCLC).
Shortages in oncology drugs “increased at an alarming rate” in just one year.
Regorafenib significantly prolongs progression-free survival (PFS) and disease control rate (DCS) among patients with advanced metastatic or unresectable gastrointestinal stromal tumor (GIST).
Carfilzomib is an effective and tolerable replacement for bortezomib for patients who are refractory to bortezomib-containing combination regimens for the treatment of multiple myeloma.
Adding cetuximab to regimens containing pemetrexed does not improve survival rates in patients with recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.
Adding everolimus (Afinitor) did not significantly improve the efficacy of weekly paclitaxel/bevacizumab in the first-line treatment of HER2-negative metastatic breast cancer.
Please login or register first to view this content.
